Ultime notizie per MiMedx Group (NASDAQ:MDXG) Azioni

MiMedx Group

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

MIMEDX GROUP INC

MiMedx Group Inc

Lake Street Sticks to Its Buy Rating for MiMedx Group (MDXG)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Option Care Health (OPCH – Research Report), Qiagen ...

Analysts Offer Insights on Healthcare Companies: Option Care Health (OPCH), Qiagen (QGEN) and MiMedx Group (MDXG)

Northland Securities analyst Carl Byrnes maintained a Buy rating on MiMedx Group (MDXG – Research Report) today and set a price target of $12.00. T...

MiMedx Group (MDXG) Gets a Buy from Northland Securities

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on MiMedx Group (MDXG – Research Report). The company's s...

Craig-Hallum Sticks to Its Buy Rating for MiMedx Group (MDXG)

Craig-Hallum Reaffirms Their Buy Rating on MiMedx Group (MDXG)

MiMedx Group Q3 2024 Earnings Preview

MiMedx Group Non-GAAP EPS of $0.07 beats by $0.03, revenue of $84M beats by $0.98M

MiMedx Group ( ($MDXG) ) has provided an announcement. MiMedx Group reported a 3% increase in net sales for Q3 2024, reaching $84 million, driven b...

MiMedx Group Reports 3% Sales Increase in Q3 2024

MiMedx Group, Inc. (MDXG) Q3 2024 Earnings Call Transcript

MiMedx Group Inc. ( ($MDXG) ) has realeased its Q3 earnings. Here is a breakdown of the information MiMedx Group Inc. presented to its investors. M...

MiMedx Group Inc. Reports Q3 2024 Financial Results

MDXG

OPCH

QGEN

Health Care

Press Releases

General

MIMEDX Announces Launch of HELIOGEN™ Fibrillar Collagen Matrix

DEFENDANT FIGHTS BACK AGAINST MiMEDX "BLATANT INTIMIDATION" NON-COMPETE SUIT

News

MIMEDX to Participate in Upcoming Investor Conferences

THIRD DEFENDANT FIGHTS BACK AGAINST MiMEDX, CLAIMING 'DISREPUTABLE AND UNLAWFUL BUSINESS PRACTICES'

EX-MiMEDX EMPLOYEES ALLEGE  MiMEDX "PRESSURE[D] HEALTHCARE PROVIDERS TO TREAT WOUNDED VETERANS, DIABETICS, CHRONIC WOUND SUFFERERS, AND OTHER PATIENTS WITH MEDICALLY UNNECESSARY OR UNSUITABLE PRODUCTS"

MIMEDX Showcases Leading Allograft Portfolio and Its Latest Scientific and Clinical Evidence at SAWC Fall

MIMEDX Points to The New York Times Article on the Vast Benefits of Placental Tissue

MIMEDX to Host Third Quarter 2024 Operating and Financial Results Conference Call on October 30

Earnings

MIMEDX Announces Third Quarter 2024 Operating and Financial Results

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

ArriVent BioPharma

Bicara Therapeutics

CareDx

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

Cogent Biosciences

Cargo Therapeutics

Erasca

89bio

Immatics

Kura Oncology

Mesoblast Limited - American Depositary Shares

Mesoblast

Neurogene

Novavax

Oruka Therapeutics

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Relay Therapeutics

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Tyra Biosciences

Upstream Bio

Vir Biotechnology

Zymeworks

Cantor Fitzgerald

Craig-Hallum

HC Wainwright & Co.

Lake Street

Mizuho

Comments

MiMedx Group

Notizie

Ultime notizie per MiMedx Group (NASDAQ:MDXG) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO